This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain Axsome Therapeutics develops therapies for central nervous system disorders, with a late-stage pipeline targeting major unmet medical needs.
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators.
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names This clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials.
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline Praxis Precision Medicines develops therapies for central nervous system disorders, targeting unmet needs in neurology and psychiatry.
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.
The Small-Cap Renaissance: Russell 2000 Eclipses Big Tech in Historic Early 2026 Surge As the first quarter of 2026 passes its midway point, a seismic shift in market leadership is unfolding on Wall Street. After years of playing second fiddle to the "Magnificent Seven" and the artificial intelligence arms race, small-cap stocks are finally having their moment in the sun. In a stunning
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions.
Large Biotech Fund Sells Shares of Cogent Biosciences for Over $120M A large biotech fund that's an insider at Cogent Biosciences recently sold millions of shares amid the company's best annual performance ever in 2025.
Cogent Insider Sells $2.5 Million in Stock Amid Staggering 300% Price Surge Focused on precision therapies for rare diseases, this biotech firm reported a significant insider sale amid a year of sharp share gains.
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters.
Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down.
Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare — and the timing may be the entire story.
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.
Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.
This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization.
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data.
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.
